RT Journal Article
SR Electronic
T1 Survival in Limited Disease Small Cell Lung Cancer According to N3 Lymph Node Involvement
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 871
OP 876
VO 38
IS 2
A1 CHRISTINE D. VALAN
A1 JENS E. SLAGSVOLD
A1 TARJE ONSØIEN HALVORSEN
A1 MARTIN HERJE
A1 ROY M. BREMNES
A1 PAAL F. BRUNSVIG
A1 ODD T. BRUSTUGUN
A1 ØYSTEIN FLØTTEN
A1 NINA LEVIN
A1 STEIN H. SUNDSTRØM
A1 BJØRN H. GRØNBERG
YR 2018
UL http://ar.iiarjournals.org/content/38/2/871.abstract
AB Background/Aim: There are several definitions of limited disease (LD) in small cell lung cancer (SCLC), differing with respect to N3 disease accepted. We analyzed patients from a randomized trial comparing two schedules of thoracic radiotherapy (TRT) in LD SCLC to investigate whether there were survival differences between N3 subcategories (n=144). Patients and Methods: Patients with a baseline CT scan available were analysed. Patients received four courses of cisplatin/etoposide and TRT of 45 Gy/30 fractions (twice daily) or 42 Gy/15 fractions (once daily). Results: Median overall survival (OS) was 23.3 months in the whole cohort. N3-patients (n=37) had shorter survival than those with N0-2 (16.7 vs. 33.0 months; p<0.001). There were no significant OS-differences between the N3 subcategories, but patients with metastases to two or more N3 regions had shorter survival than other N3 patients (13.4 vs. 19.9 months; p=0.011). Conclusion: There were no survival differences between the N3 subcategories, suggesting that all N3 disease should be considered as LD.